ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ILMN Stock Price » ILMN Stock News

Illumina Share News

 Illumina (mm) Stock Price
ILMN Stock Price
 Illumina (mm) Stock Chart
ILMN Stock Chart
 Illumina (mm) Stock News
ILMN Stock News
 Illumina (mm) Company Information
ILMN Company Information
 Illumina (mm) Stock Trades
ILMN Stock Trades

Roche Doesn't Plan To Extend Bid For Illumina

DOW JONES NEWSWIRES Roche Holding AG (ROG.VX) said it doesn't plan to extend its unsolicited takeover bid worth more than $6.5 billion for Illumina Inc. (ILMN) past Friday's deadline, citing preliminary estimates indicating that the incumbents on the U.S. gene-sequencing company's will be re-elected. "We do not believe that a price above Roche's offer for Illumina of $51 per share would be in the interest of Roche's shareholders," Roche Chief Executive Severin Schwan said. Ilumina shares were down 9% at $40 in recent premarket trading. Through Wednesday's close the stock was up 44% this year amid the takeover offer. A Roche unit had proposed amending Illumina's bylaws to increase the number of directors on its board and offered two individuals to fill the new slots. If all Roche's proposals were adopted and its nominees elected, Roche's nominees would have constituted a majority of Illumina's board. Three proxy advisory firms had recommended that Illumina's shareholders vote against Roche's slate, and Illumina's board has recommended shareholders reject the proposals. Roche recently raised its offer for Illumina, but the company has continued to spurn the offer as undervaluing its "extraordinary" growth prospects. Roche has called its bid "full, fair and extremely attractive." The world's largest maker of cancer drugs had launched the hostile takeover attempt in late January in part of a search for ways to expand its offerings in the burgeoning personalized-medicine market. -By Tess Stynes and Joan E. Solsman, Dow Jones Newswires; 212-416-2481;

Stock News for Illumina (ILMN)
03/31/201521:40:01Individual Investor Portfolio: Select Sectors And Companies Continue...
03/31/201518:02:16Statement of Changes in Beneficial Ownership (4)
03/31/201509:19:00Berry Genomics NextSeq CN500 Instrument and Non-Invasive Prenatal...
03/19/201519:53:52Statement of Changes in Beneficial Ownership (4)
03/18/201508:31:00Matthew Posard Joins Trovagene's Executive Management Team as...
03/16/201518:47:33Statement of Changes in Beneficial Ownership (4)
03/16/201518:22:42Statement of Changes in Beneficial Ownership (4)
03/16/201504:05:00Illumina Files Patent Infringement Suit in the United Kingdom...
03/13/201519:37:42Statement of Changes in Beneficial Ownership (4)
03/12/201517:56:41Statement of Changes in Beneficial Ownership (4)
03/11/201519:48:34Statement of Changes in Beneficial Ownership (4)
03/11/201519:48:34Statement of Changes in Beneficial Ownership (4)
03/11/201519:48:12Statement of Changes in Beneficial Ownership (4)
03/11/201519:47:43Statement of Changes in Beneficial Ownership (4)
03/11/201519:47:43Statement of Changes in Beneficial Ownership (4)
03/11/201519:47:21Statement of Changes in Beneficial Ownership (4)
03/10/201509:00:00Illumina Announces Strategic Collaboration with Merck Serono...
03/09/201503:59:30Looking Back At 2014 And What To Expect In 2015 For Sequenom
03/04/201506:30:00Illumina Launches TruSight HLA Solution
02/26/201506:30:00Illumina Accelerator Secures $40 Million Boost Capital to Back...

Illumina and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations